- Home
- EDU vs RVMD Comparison
EDU vs RVMD Comparison
Compare EDU & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- RVMD
- Stock Information
- Founded
- EDU 1993
- RVMD 2014
- Country
- EDU China
- RVMD United States
- Employees
- EDU N/A
- RVMD N/A
- Industry
- EDU Other Consumer Services
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDU Real Estate
- RVMD Health Care
- Exchange
- EDU Nasdaq
- RVMD Nasdaq
- Market Cap
- EDU 7.7B
- RVMD 7.5B
- IPO Year
- EDU 2006
- RVMD 2020
- Fundamental
- Price
- EDU $47.61
- RVMD $37.01
- Analyst Decision
- EDU Hold
- RVMD Strong Buy
- Analyst Count
- EDU 5
- RVMD 13
- Target Price
- EDU $51.60
- RVMD $69.85
- AVG Volume (30 Days)
- EDU 1.5M
- RVMD 1.9M
- Earning Date
- EDU 07-30-2025
- RVMD 08-06-2025
- Dividend Yield
- EDU 1.22%
- RVMD N/A
- EPS Growth
- EDU 27.50
- RVMD N/A
- EPS
- EDU 2.29
- RVMD N/A
- Revenue
- EDU $4,900,262,000.00
- RVMD N/A
- Revenue This Year
- EDU $12.40
- RVMD N/A
- Revenue Next Year
- EDU $12.56
- RVMD $234.26
- P/E Ratio
- EDU $20.62
- RVMD N/A
- Revenue Growth
- EDU 13.60
- RVMD N/A
- 52 Week Low
- EDU $40.66
- RVMD $29.17
- 52 Week High
- EDU $87.26
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- EDU 51.17
- RVMD 51.77
- Support Level
- EDU $46.60
- RVMD $35.42
- Resistance Level
- EDU $49.18
- RVMD $37.89
- Average True Range (ATR)
- EDU 1.04
- RVMD 1.37
- MACD
- EDU 0.27
- RVMD 0.16
- Stochastic Oscillator
- EDU 61.01
- RVMD 65.43
About EDU New Oriental Education & Technology Group Inc.
New Oriental is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation, consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.